Plain-English difference
MOTS-c is a mitochondrial signal peptide; creatine supports rapid cellular energy recycling
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA and studied for metabolic signaling, including AMPK-related pathways. Creatine is converted to phosphocreatine, which helps recycle ATP during brief, high-intensity activity. That distinction matters: MOTS-c marketing often emphasizes metabolism, glucose handling, exercise-mimetic language, and healthy aging, while creatine is commonly discussed for repeated high-intensity effort and resistance-training adaptation. Neither category should be chosen from mechanism language alone.
- MOTS-c should not be described as an FDA-approved exercise, obesity, osteoporosis, diabetes, fatigue, muscle-building, or longevity treatment.
- Creatine monohydrate has human performance and training research, but a supplement label does not guarantee purity, suitability, or a specific result.
- Compounded medications, when lawful and clinically appropriate, are individualized prescriptions and are not FDA-approved finished drug products.
Evidence quality
Creatine has more direct human outcome data; MOTS-c evidence remains early
A landmark MOTS-c study reported metabolic effects in cells and mice, not proof of treatment benefit in patients. A small human exercise study found that acute endurance exercise changed circulating mitochondrial-derived peptides, including MOTS-c; a naturally occurring biomarker response does not establish that administered MOTS-c improves performance or metabolic outcomes. By contrast, systematic reviews of creatine combined with resistance training report measurable effects on some muscle and strength outcomes, with differences by population, training program, body region, and study design. That stronger evidence base still does not make creatine a substitute for diagnosis, nutrition, progressive training, rehabilitation, sleep, or indicated medical care.
- Ask whether a claim comes from cells, animals, observational biomarkers, a randomized human trial, or a systematic review of the exact intervention and outcome.
- Do not treat “exercise mimetic” as meaning MOTS-c replaces exercise, and do not treat creatine as guaranteed muscle gain without an appropriate training stimulus.
- Fatigue, weakness, unexplained weight change, exercise intolerance, or poor recovery may warrant evaluation for sleep, nutrition, anemia, thyroid, cardiac, pulmonary, metabolic, medication, mood, infection, or overtraining causes.
Regulatory context
The July 2026 FDA PCAC review is not MOTS-c approval
FDA scheduled MOTS-c free base and acetate for discussion at the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting as part of the section 503A bulks-list process, with obesity and osteoporosis identified as nominated uses in FDA meeting materials. This is an advisory compounding-policy review—not FDA approval, proof of effectiveness, an exercise recommendation, dosing guidance, or validation of online peptide sellers. Creatine products follow the dietary-supplement framework rather than the prescription-drug approval pathway, so consumers still need to evaluate the finished product, label, ingredients, testing, and claims.
- Treat “FDA-approved MOTS-c,” “approved in July,” and “legal research peptide for human use” claims as red flags.
- FDA-approved drugs, individualized compounded prescriptions, investigational substances, research-use products, and dietary supplements are different categories.
- PCAC recommendations are advisory; FDA makes final determinations after considering committee input and completed reviews.
Safety and monitoring
Kidney, glucose, hydration, and full-stack context can change the decision
MOTS-c lacks an FDA-approved label establishing indications, dosing, contraindications, interactions, or long-term safety. Creatine studies generally report tolerability in studied adults, but patients should still discuss kidney disease, abnormal kidney tests, dehydration risk, pregnancy, other supplements, and medicines with a clinician. Creatine can also affect serum creatinine interpretation, so the clinician ordering kidney tests should know it is being used. For MOTS-c, glucose-lowering medicines and changing glucose readings deserve particular attention because internet metabolic claims should not become self-directed diabetes treatment.
- Do not stop or adjust insulin, sulfonylureas, GLP-1 medicines, metformin, blood-pressure medicines, diuretics, or other prescriptions to accommodate either product without the prescriber.
- Check whether a creatine product is single-ingredient creatine monohydrate or a multi-ingredient pre-workout containing stimulants, sweeteners, herbs, or undisclosed blends.
- Seek prompt care for chest pain, fainting, severe shortness of breath, confusion, severe weakness, persistent vomiting, signs of serious allergy, or symptoms of severe low blood sugar.
Sports, sourcing, and cost
Compare the complete pathway—not a vial, tub, or monthly price
A MOTS-c pathway can involve medical evaluation, labs, an individualized prescription if clinically appropriate, licensed-pharmacy dispensing, cold-chain handling, adverse-event instructions, and follow-up. A creatine pathway may look simpler, but product identity, dose disclosure, third-party testing, other ingredients, training fit, and medication-list review still matter. Tested athletes should verify current anti-doping and governing-body rules for every peptide, medication, supplement, and ingredient rather than relying on a seller or “natural” label.
- No-prescription MOTS-c checkout, research-use labeling aimed at patients, copied cycles, vague pharmacy sourcing, and guaranteed metabolic or performance outcomes are red flags.
- For creatine, avoid proprietary blends that hide ingredient amounts, stimulant-heavy products, disease-treatment claims, counterfeit seals, and sellers without traceable contact or lot information.
- A credible plan defines the goal, objective measures, expected review point, side-effect response, total cost, and when to stop rather than adding products indefinitely.